BIO-TECHNE Corp (TECH) Operating Margin
- Operating margin · 12 months: Value 20.73%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 20.73% | Operating income / revenue. Period ending 2026-06-30. $251.89M ÷ $1.22B × 100 ≈ 20.73% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 251.89M USD | Operating Income (Loss) |
| Revenue | 1.22B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 415.97M USD | Cost of Goods and Services Sold |
| Research and development | (m) | |
| Selling, general and administration | 452.42M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $251.89M | $1.22B | $415.97M | (m) | $452.42M | 20.73% |
| 2026-03-31 | $153.75M | $1.21B | $424.32M | (m) | $535.88M | 12.70% |
| 2025-12-31 | $116.97M | $1.22B | $422.82M | (m) | $577.81M | 9.62% |
| 2025-09-30 | $109.93M | $1.22B | $421.37M | (m) | $585.57M | 9.03% |
| 2025-06-30 | $102.25M | $1.22B | $429.36M | (m) | $588.52M | 8.38% |
| 2025-03-31 | $171.94M | $1.21B | $413.96M | (m) | $525.42M | 14.22% |
| 2024-12-31 | $200.23M | $1.20B | $411.17M | (m) | $485.99M | 16.74% |
| 2024-09-30 | $190.81M | $1.17B | $404.03M | (m) | $480.20M | 16.29% |
| 2024-06-30 | $206.69M | $1.16B | $389.33M | (m) | $466.38M | 17.83% |
| 2024-03-31 | $255.39M | $1.15B | $383.21M | (m) | $419.59M | 22.13% |
| 2023-12-31 | $268.60M | $1.14B | $376.36M | (m) | $406.99M | 23.46% |
| 2023-09-30 | $298.49M | $1.14B | $368.57M | (m) | $384.33M | 26.09% |
| 2023-06-30 | $298.94M | $1.14B | $366.89M | (m) | $378.38M | 26.30% |
| 2023-03-31 | $284.99M | $1.12B | $358.14M | (m) | $388.25M | 25.36% |
| 2022-12-31 | $295.23M | $1.12B | $355.08M | (m) | $378.28M | 26.36% |
| 2022-09-30 | $289.69M | $1.12B | $352.44M | (m) | $385.97M | 25.92% |
| 2022-06-30 | $296.59M | $1.11B | $349.10M | (m) | $372.77M | 26.83% |
| 2022-03-31 | $284.60M | $1.08B | $344.31M | (m) | $362.78M | 26.44% |
| 2021-12-31 | $262.78M | $1.03B | $330.67M | (m) | $356.11M | 25.52% |
| 2021-09-30 | $251.43M | $984.55M | $318.44M | (m) | $338.53M | 25.54% |
| 2021-06-30 | $237.30M | $931.03M | $298.18M | (m) | $324.95M | 25.49% |
| 2021-03-31 | $208.02M | $847.84M | $277.62M | (m) | $295.54M | 24.54% |
| 2020-12-31 | $187.19M | $798.97M | $266.96M | (m) | $279.26M | 23.43% |
| 2020-09-30 | $173.18M | $759.65M | $257.14M | (m) | $264.17M | 22.80% |
| 2020-06-30 | $157.42M | $738.69M | $255.50M | (m) | $260.58M | 21.31% |
| 2020-03-31 | $161.37M | $754.52M | $256.38M | (m) | $272.10M | 21.39% |
| 2019-12-31 | $157.67M | $744.70M | $252.02M | (m) | $270.74M | 21.17% |
| 2019-09-30 | $154.28M | $734.28M | $249.98M | (m) | $266.32M | 21.01% |
| 2019-06-30 | $146.72M | $714.01M | $240.51M | (m) | $264.36M | 20.55% |
| 2019-03-31 | $146.37M | (m) | $235.18M | (m) | $260.91M | (m) |
| 2018-12-31 | $145.36M | (m) | $228.65M | (m) | $249.23M | (m) |
| 2018-09-30 | $135.91M | (m) | $219.47M | (m) | $249.40M | (m) |
| 2018-06-30 | $136.18M | (m) | $210.85M | (m) | $240.64M | (m) |
| 2018-03-31 | $133.31M | (m) | $206.98M | (m) | $223.98M | (m) |
| 2017-12-31 | $123.73M | $599.38M | $200.63M | (m) | $220.10M | 20.64% |
| 2017-09-30 | $117.46M | $577.03M | $191.97M | (m) | $213.31M | 20.36% |
| 2017-06-30 | $120.58M | $563.00M | $188.46M | (m) | $200.44M | 21.42% |
| 2017-03-31 | $113.90M | $541.19M | $187.76M | (m) | $188.06M | 21.05% |
| 2016-12-31 | $125.13M | $528.12M | $178.89M | (m) | $175.17M | 23.69% |
| 2016-09-30 | $145.01M | $517.22M | $171.49M | (m) | $154.10M | 28.04% |
| 2016-06-30 | $150.59M | $499.02M | $162.36M | (m) | $140.88M | 30.18% |
| 2016-03-31 | $1.51M | $481.92M | $155.87M | (m) | $133.32M | 0.31% |
| 2015-12-31 | $-2.59M | $465.11M | $149.66M | (m) | $127.19M | -0.56% |
| 2015-09-30 | $-4.04M | $456.15M | $146.55M | (m) | $123.74M | -0.89% |
| 2015-06-30 | $147.02K | $452.25M | $144.97M | (m) | $119.40M | 0.03% |
| 2015-03-31 | $148.07M | $427.11M | $135.32M | (m) | $106.03M | 34.67% |
| 2014-12-31 | $154.41M | $408.50M | $127.99M | (m) | $91.61M | 37.80% |
| 2014-09-30 | $155.57M | $380.57M | $117.21M | (m) | $75.40M | 40.88% |
| 2014-06-30 | $159.75M | $357.76M | $106.35M | (m) | $60.72M | 44.65% |
| 2014-03-31 | $160.72M | $344.71M | $97.78M | (m) | $55.73M | 46.62% |
| 2013-12-31 | $158.90M | $330.15M | $90.18M | (m) | $51.05M | 48.13% |
| 2013-09-30 | $160.06M | $321.22M | $84.58M | (m) | $47.08M | 49.83% |
| 2013-06-30 | $158.47M | $310.57M | $79.47M | (m) | $43.38M | 51.02% |
| 2013-03-31 | $159.87M | $309.78M | $78.92M | (m) | $41.63M | 51.61% |
| 2012-12-31 | $162.29M | $312.41M | $79.32M | (m) | $41.54M | 51.95% |
| 2012-09-30 | $163.06M | $311.99M | $78.99M | (m) | $41.24M | 52.27% |
| 2012-06-30 | $166.21M | $314.56M | $78.76M | (m) | $41.68M | 52.84% |
| 2012-03-31 | $167.59M | $313.92M | $77.35M | (m) | $41.88M | 53.39% |
| 2011-12-31 | $165.97M | $306.57M | $73.05M | (m) | $41.28M | 54.14% |
| 2011-09-30 | $165.64M | $299.61M | $68.88M | (m) | $39.06M | 55.28% |
| 2011-06-30 | $163.06M | $289.96M | $65.03M | (m) | $35.90M | 56.23% |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $156.33M | $269.05M | $54.90M | (m) | $32.70M | 58.10% |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | $150.78M | $263.96M | $55.92M | (m) | $33.69M | 57.12% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |